CY1107388T1 - Αγωνιστες αλφα υποδοχεα ενεργοποιουμενου απο πολλαπλασιαστες υπεροξυσωματων - Google Patents
Αγωνιστες αλφα υποδοχεα ενεργοποιουμενου απο πολλαπλασιαστες υπεροξυσωματωνInfo
- Publication number
- CY1107388T1 CY1107388T1 CY20081100391T CY081100391T CY1107388T1 CY 1107388 T1 CY1107388 T1 CY 1107388T1 CY 20081100391 T CY20081100391 T CY 20081100391T CY 081100391 T CY081100391 T CY 081100391T CY 1107388 T1 CY1107388 T1 CY 1107388T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- cycloalkyl
- group selected
- Prior art date
Links
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 150000003857 carboxamides Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/22—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups further bound to nitrogen atoms, e.g. hydrazidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/02—Compounds containing any of the groups, e.g. carbazates
- C07C281/04—Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Cultivation Of Plants (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η παρούσα εφεύρεση εστιάζεται σε ενώσεις οι οποίες αντιπροσωπεύονται από τον ακόλουθο δομικό τύπο (Ι'), και φαρμακευτικώς αποδεκτά άλατα, επιδιαλυτωμένα άλατα και ένυδρα άλατα αυτών, το R1 είναι μια υποκατεστημένη ή μη-υποκατεστημένη ομάδα επιλεγμένη από C1-C8 αλκύλιο, αρυλο-C0-2-αλκύλιο, ετεροαρυλο-C0-2-αλκύλιο, C3-C6 κυκλοαλκυλαρυλο-C0-2-αλκύλιο ή φαινύλιο. To W είναι Ο ή S. To R2 είναι Η ή μια υποκατεστημένη ή μη-υποκατεστημένη ομάδα επιλεγμένη από C1-C6 αλκύλιο, C3-C6 κυκλοαλκύλιο και ετεροαρύλιο. To Χ είναι ένας C2-C5 αλκυλενο συνδέτης όπου ένα άτομο άνθρακα του συνδέτη μπορεί να αντικατασταθεί με Ο, ΝΗ, ή S. Το Υ είναι C, Ο, S, ΝΗ ή ένας απλός δεσμός. Περαιτέρω, το Ε είναι (CH2)nCOOH, όπου το n είναι 0, 1, 2 ή 3, ή C(R3)(R4)A, όπου το Α είναι μια όξινη δραστική ομάδα όπως καρβοξύλιο, καρβοξαμίδιο υποκατεστημένο ή μη-υποκατεστημένο σουλφοναμίδιο, ή υποκατεστημένο ή μη-υποκατεστημένο τετραζόλιο. To R3 είναι Η, κορεσμένο ή ακόρεστο C1-C5 αλκύλιο, C1-C5 αλκοξυ. Επιπροσθέτως, το R4 είναι Η, αλογόνο, μια υποκατεστημένη ή μη-υποκατεστημένη ομάδα επιλεγμένη από C1-C5 αλκύλιο, C1-C5 αλκοξυ, C3-C6 κυκλοαλκύλιο, αρυλοC0-C4αλκύλιο και φαινύλιο, ή τα R3 και R4 συνδυάζονται για να σχηματίσουν ένα C3-C4 κυκλοαλκύλιο.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24731700P | 2000-11-10 | 2000-11-10 | |
| EP01989704A EP1335908B1 (en) | 2000-11-10 | 2001-11-09 | Peroxisome proliferator activated receptor alpha agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107388T1 true CY1107388T1 (el) | 2012-12-19 |
Family
ID=22934453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100391T CY1107388T1 (el) | 2000-11-10 | 2008-04-10 | Αγωνιστες αλφα υποδοχεα ενεργοποιουμενου απο πολλαπλασιαστες υπεροξυσωματων |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US7304062B2 (el) |
| EP (1) | EP1335908B1 (el) |
| JP (1) | JP4243101B2 (el) |
| KR (1) | KR100839705B1 (el) |
| CN (1) | CN1479728A (el) |
| AR (1) | AR031305A1 (el) |
| AT (1) | ATE386026T1 (el) |
| AU (3) | AU2859202A (el) |
| BR (1) | BR0114986A (el) |
| CA (1) | CA2421154A1 (el) |
| CY (1) | CY1107388T1 (el) |
| CZ (1) | CZ20031283A3 (el) |
| DE (1) | DE60132799T2 (el) |
| DK (1) | DK1335908T3 (el) |
| EA (1) | EA006920B1 (el) |
| EC (1) | ECSP034595A (el) |
| ES (1) | ES2300378T3 (el) |
| HR (1) | HRP20030365A2 (el) |
| HU (1) | HUP0301655A2 (el) |
| IL (2) | IL154840A0 (el) |
| MX (1) | MXPA03004141A (el) |
| MY (1) | MY157884A (el) |
| NO (1) | NO20032059L (el) |
| NZ (1) | NZ524569A (el) |
| PE (1) | PE20020693A1 (el) |
| PL (1) | PL362692A1 (el) |
| PT (1) | PT1335908E (el) |
| SI (1) | SI1335908T1 (el) |
| SK (1) | SK5412003A3 (el) |
| SV (1) | SV2003000727A (el) |
| TW (1) | TW200716572A (el) |
| UA (1) | UA82048C2 (el) |
| WO (1) | WO2002038553A2 (el) |
| ZA (1) | ZA200302517B (el) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003043997A1 (en) * | 2001-11-15 | 2003-05-30 | Eli Lilly And Company | Peroxisome proliferator activated receptor alpha agonists |
| GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| AU2003241579B9 (en) | 2002-06-19 | 2009-07-30 | Eli Lilly And Company | Amide linker peroxisome proliferator activated receptor modulators |
| TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
| FR2866339B1 (fr) * | 2004-02-18 | 2006-05-05 | Pf Medicament | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| KR100803481B1 (ko) * | 2004-07-27 | 2008-02-14 | 에프. 호프만-라 로슈 아게 | 비-뉴클레오사이드 역전사효소 억제제로서의벤질트라이아졸론 화합물 |
| US8293778B2 (en) | 2004-07-27 | 2012-10-23 | Roche Palo Alto Llc | Heterocyclic antiviral compounds |
| CA2574308C (en) * | 2004-07-27 | 2014-03-25 | F. Hoffmann-La Roche Ag | Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors |
| BRPI0515015A (pt) * | 2004-08-11 | 2008-07-01 | Kyorin Seiyaku Kk | derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável |
| WO2006068199A1 (ja) * | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体 |
| PE20061041A1 (es) * | 2005-01-28 | 2006-10-12 | Lilly Co Eli | Formulaciones y regimen de dosificacion para moduladores alfa de ppar |
| FR2882750B1 (fr) * | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| EP1862464A4 (en) * | 2005-03-23 | 2010-08-25 | Kyorin Seiyaku Kk | NEW CYCLIC AMINOPHENYL ALKANIC ACID DERIVATIVE |
| CN101180280A (zh) * | 2005-03-24 | 2008-05-14 | 弗·哈夫曼-拉罗切有限公司 | 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物 |
| JP5225076B2 (ja) * | 2006-04-27 | 2013-07-03 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体の医薬用途 |
| EA200970793A1 (ru) * | 2007-02-23 | 2010-02-26 | Эли Лилли Энд Компани | Модуляторы рецепторов, активируемых пролифераторами пероксисом |
| CA2682637A1 (en) | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| WO2010002712A2 (en) * | 2008-06-30 | 2010-01-07 | 3M Innovative Properties Company | Method of crystallization |
| CN101643451B (zh) * | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
| AU2009323367B2 (en) | 2008-12-01 | 2013-05-23 | Mitsubishi Tanabe Pharma Corporation | Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof |
| US20110167512A1 (en) * | 2009-03-02 | 2011-07-07 | Nunhems B.V. | Hybrid artichoke variety nun 4006 ar |
| US8575430B2 (en) * | 2010-03-02 | 2013-11-05 | Nunhems, B.V. | Hybrid artichoke variety NUN 4006 AR |
| DE102010001064A1 (de) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| US20100245582A1 (en) * | 2009-03-25 | 2010-09-30 | Syclipse Technologies, Inc. | System and method of remote surveillance and applications therefor |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US8648233B2 (en) * | 2010-09-20 | 2014-02-11 | Nunhems B.V. | Hybrid artichoke variety NUN 4021 AR |
| US8669420B2 (en) | 2012-02-29 | 2014-03-11 | Nunhems B.V. | Hybrid artichoke variety NUN 4060 AR |
| WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| JP6404230B2 (ja) | 2012-12-20 | 2018-10-10 | インセプション ２、 インコーポレイテッド | トリアゾロン化合物およびその使用 |
| EA201690230A1 (ru) * | 2013-09-06 | 2016-07-29 | Инсепшн 2, Инк. | Соединения триазолона и их применения |
| RU177130U1 (ru) * | 2017-11-29 | 2018-02-09 | Владимир Алексеевич Коннов | Плита изоляционная облицовочная |
| JPWO2021205803A1 (el) | 2020-04-10 | 2021-10-14 | ||
| CN112774869B (zh) * | 2020-12-25 | 2022-09-16 | 厦门紫金矿冶技术有限公司 | 黄铁矿抑制剂及其制备和在铜铅锌多金属硫化矿中的应用 |
| CN114853686B (zh) * | 2021-08-23 | 2023-06-20 | 中国药科大学 | 三氮唑酮类化合物及其医药用途 |
| CN115894379B (zh) * | 2022-01-20 | 2025-06-27 | 哈尔滨三联药业股份有限公司 | 海因类化合物及其医药用途 |
| CN114563394B (zh) * | 2022-02-10 | 2025-03-11 | 湖南东方钪业股份有限公司 | 一种氟化钪中杂质含量的检测方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2090283A1 (en) * | 1992-02-28 | 1993-08-29 | Nobuyuki Hamanaka | Phenoxyacetic acid derivatives |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| DE19517505A1 (de) | 1995-05-12 | 1996-11-14 | Bayer Ag | Sulfonylamino(thio)carbonyltriazolin(thi)one mit Aryloxy- oder Arylthio-Substituenten |
| EP0858457A1 (de) * | 1995-10-20 | 1998-08-19 | Dr. Karl Thomae GmbH | 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung |
| TW557295B (en) | 1997-10-17 | 2003-10-11 | Yamanouchi Pharma Co Ltd | Amide derivatives or salts thereof |
| WO1999008501A2 (en) | 1998-04-23 | 1999-02-25 | Dr. Reddy's Research Foundation | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| USPP14578P2 (en) * | 2002-09-23 | 2004-03-09 | Plant Sciences, Inc. | Artichoke plant named ‘PS-MSC0003’ |
-
2001
- 2001-09-11 UA UA2003054187A patent/UA82048C2/uk unknown
- 2001-11-07 AR ARP010105214A patent/AR031305A1/es unknown
- 2001-11-08 PE PE2001001108A patent/PE20020693A1/es not_active Application Discontinuation
- 2001-11-08 MY MYPI20015155A patent/MY157884A/en unknown
- 2001-11-08 TW TW095138799A patent/TW200716572A/zh unknown
- 2001-11-09 PL PL01362692A patent/PL362692A1/xx unknown
- 2001-11-09 PT PT01989704T patent/PT1335908E/pt unknown
- 2001-11-09 AU AU2859202A patent/AU2859202A/xx active Pending
- 2001-11-09 MX MXPA03004141A patent/MXPA03004141A/es active IP Right Grant
- 2001-11-09 KR KR1020037006301A patent/KR100839705B1/ko not_active Expired - Fee Related
- 2001-11-09 JP JP2002541088A patent/JP4243101B2/ja not_active Expired - Fee Related
- 2001-11-09 SI SI200130828T patent/SI1335908T1/sl unknown
- 2001-11-09 NZ NZ524569A patent/NZ524569A/en unknown
- 2001-11-09 CZ CZ20031283A patent/CZ20031283A3/cs unknown
- 2001-11-09 CN CNA018185878A patent/CN1479728A/zh active Pending
- 2001-11-09 EA EA200300558A patent/EA006920B1/ru not_active IP Right Cessation
- 2001-11-09 AT AT01989704T patent/ATE386026T1/de not_active IP Right Cessation
- 2001-11-09 WO PCT/US2001/042928 patent/WO2002038553A2/en not_active Ceased
- 2001-11-09 US US10/415,673 patent/US7304062B2/en not_active Expired - Fee Related
- 2001-11-09 BR BR0114986-5A patent/BR0114986A/pt not_active IP Right Cessation
- 2001-11-09 DK DK01989704T patent/DK1335908T3/da active
- 2001-11-09 SK SK541-2003A patent/SK5412003A3/sk not_active Application Discontinuation
- 2001-11-09 DE DE60132799T patent/DE60132799T2/de not_active Expired - Fee Related
- 2001-11-09 ES ES01989704T patent/ES2300378T3/es not_active Expired - Lifetime
- 2001-11-09 HR HR20030365A patent/HRP20030365A2/hr not_active Application Discontinuation
- 2001-11-09 IL IL15484001A patent/IL154840A0/xx unknown
- 2001-11-09 AU AU2002228592A patent/AU2002228592B8/en not_active Ceased
- 2001-11-09 HU HU0301655A patent/HUP0301655A2/hu unknown
- 2001-11-09 EP EP01989704A patent/EP1335908B1/en not_active Expired - Lifetime
- 2001-11-09 CA CA002421154A patent/CA2421154A1/en not_active Abandoned
- 2001-11-09 SV SV2001000727A patent/SV2003000727A/es not_active Application Discontinuation
-
2003
- 2003-03-10 IL IL154840A patent/IL154840A/en active IP Right Grant
- 2003-03-31 ZA ZA200302517A patent/ZA200302517B/en unknown
- 2003-05-08 EC EC2003004595A patent/ECSP034595A/es unknown
- 2003-05-08 NO NO20032059A patent/NO20032059L/no unknown
-
2006
- 2006-06-29 AU AU2006202811A patent/AU2006202811A1/en not_active Abandoned
-
2007
- 2007-07-26 US US11/828,446 patent/US20090062358A1/en not_active Abandoned
-
2008
- 2008-04-10 CY CY20081100391T patent/CY1107388T1/el unknown
- 2008-06-27 US US12/215,466 patent/US7868225B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107388T1 (el) | Αγωνιστες αλφα υποδοχεα ενεργοποιουμενου απο πολλαπλασιαστες υπεροξυσωματων | |
| CY1105899T1 (el) | Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες | |
| CY1112914T1 (el) | Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης | |
| CY1107886T1 (el) | Αναστολεις κινασης ως θεραπευτικοι παραγοντες | |
| CY1108313T1 (el) | Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6 | |
| ATE415160T1 (de) | Modulatoren von peroxisome proliferator- aktivierten rezeptoren | |
| CY1113657T1 (el) | Νεα παραγωγα βενζοφαινονης ή αλατα αυτων | |
| CY1108352T1 (el) | Υποκατασταθεισες 1,4-βενζοδιαζεπινες και χρησεις τους για την αγωγη του καρκινου | |
| CO4970713A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
| CY1106947T1 (el) | Ανταγωνιστες υποδοχεα θρομβινης | |
| CO5150173A1 (es) | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv | |
| CO5611126A2 (es) | Derivados de indolinona utiles como inhibidores de la proteina cinasa | |
| FI980175L (fi) | 2-sulfonamidofenonijohdannaisia | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| ES2192520T3 (es) | Composicion farmaceutica. | |
| DK0502169T3 (da) | Piperazinderivater | |
| EA200300982A1 (ru) | Гетероциклические производные для лечения рака и других пролиферативных заболеваний | |
| EA200400748A1 (ru) | Агонисты рецепторов, активируемых пероксисомным пролифератором | |
| CO5611152A2 (es) | Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen | |
| EA200100310A1 (ru) | Кислородсодержащие гетероциклические соединения | |
| EA200701779A1 (ru) | Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии | |
| HRP20050390A2 (en) | Substituted benzoxazinones and uses thereof | |
| DE60327922D1 (de) | Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren | |
| DK0677042T3 (da) | Selektive ligander af 5HT1D-5HT1B-receptorer, der er afledt af indolpiperazin og er nyttige som lægemidler | |
| EA200200729A1 (ru) | Производные 4-фенил-1-пиперазинила, -пиперидинила и -тетрагидропиридила |